Grand Pharma’s TLX101 Accepted for NMPA Review for Glioblastoma Treatment
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that an Investigational New Drug (IND)...
Forlong Biotechnology Secures Series A Funding for Protein Drug Development
Forlong Biotechnology, a synthetic immunology-driven protein drug developer based in Suzhou, has reportedly raised upwards...
Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06
Shanghai Zhimeng Biopharma Inc. has announced the signing of a global licensing agreement with UK...
Haisco Pharmaceutical Announces Public Offering for Clinical Studies
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) is set to make another public offering...
BDgene’s CRISPR-Cas9 Therapy BD111 Accepted for CDE Review
Shanghai BDgene Technology Co., Ltd has announced that a clinical trial filing for its BD111,...
JunTop Biosciences’ COVID-19 Therapy Mindewei Priced at RMB 795 per Course
Sichuan’s provincial Healthcare Security Administration bureau has notified that Shanghai JunTop Biosciences Co., Ltd’s COVID-19...
Ji Xing Pharmaceuticals Acquires Global Rights to PhaseBio’s PB6440
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, has announced a deal to obtain global...
Mabwell’s Novel ADC 9MW2921 Accepted for NMPA Review
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing...
Amgen Reports Q4 and Full-Year 2022 Financials with Global Sales Growth
US major Amgen (NASDAQ: AMGN) has released its Q4 and full-year 2022 financials. Global sales...
GSK Reports Strong Q4 and Full-Year 2022 Financials Amid Strategic Shift
UK-based GlaxoSmithKline plc (NYSE: GSK) has released its financial report for Q4 and the full-year...
China’s NMPA Releases 64th Batch of Reference Drugs for Generic Quality Consistency Evaluation
China’s National Medical Products Administration (NMPA) has released the 64th batch of reference drugs for...
Bristol-Myers Squibb’s Ozanimod Approved in China for Multiple Sclerosis
Bristol-Myers Squibb (BMS, NYSE: BMY) has announced receiving marketing approval from China’s National Medical Products...
Roche Reports 2% YOY Growth in 2022; Ocrevus and Hemlibra Drive Sales
Swiss pharmaceutical giant Roche (SWX: RO) released its 2022 financial report this week, recording CHF...
Merck & Co. Posts 22% YOY Sales Growth; Keytruda and Gardasil Drive Revenues
Merck & Co. (NYSE: MRK) has released its Q4 and full-year 2022 financial report, showcasing...
Takeda Posts Strong Q3 Results, Announces Pipeline Advances in Oncology and Rare Diseases
Japan-based pharmaceutical giant Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the...
GenScript’s CAR-T Therapy Carvykti Achieves $55M in Sales, Awaits China Approval
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that sales of...
Zhejiang Gongdong to Acquire Trademark Plastics for Overseas Expansion
China-based Zhejiang Gongdong Medical Technology Co., Ltd is set to acquire core assets of US...
Innovent Biologics Posts Strong Q4 Revenues Amid COVID-19 Challenges
Innovent Biologics Inc. (HKG: 1801) announced product revenues of RMB 1 billion (USD 148.2 million)...
Shanghai Weimu Medical Raises Pre-Series A+ Funding for Clinical Development
China-based high-end interventional device maker Shanghai Weimu Medical Technology Co., Ltd has reportedly raised “tens...
MicroPort Endovascular Plans RMB 2.55 Billion Private Placement
China-based Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) plans to raise up to RMB...